Bavarian Nordic — Maj 2021
-
@Pensionisten - ja, nu må vi se
-
In 2021, Zealand Pharma expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand Pharma does not intend to provide guidance on such revenue.
Net operating expenses in 2021 are expected to be DKK 1,250 million +/-10%. -
Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection
Company announcement – No. 29/ 2021 Interim report for Q1 2021 Zealand Pharma receives first FDA approval and prepares for launch of...
GlobeNewswire News Room (www.globenewswire.com)
-
CC kl. 16.00:
https://edge.media-server.com/mmc/p/3v88gxa -
-
Zegalogue (instructions for Use):
https://www.zegalogue.com/zegalogue-autoinjector-instruction-for-use.pdf
-
Stacey talks with Frank Sanders, President of Zealand Pharma U.S. and Dr. David Kendall, Senior Global Medical Advisor. This interview covers everything from the use of Zegalogue now to cost and a look at how far treatments have come.
(Zegalogue: The Newest Easy-To-Use Rescue Glucagon)
-
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights:
Gvoke
quarterly net sales of $8.1 million -
Udover Q&A mandag med Genmab har Proinvestor sammen med Nordnet biotekwebinar med Genmab, Bavarian og Zealand Pharma tirsdag. Tlmelding: https://events.nordnet.dk/nordnet-events/kom-helt-taet-paa-tre-biotekvirksomheder-bavarian-zealand-pharma-genmab/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind